Author: Sally Pipes

Home > Articles posted by Sally Pipes (Page 11)

July 24, 2020 Issues, Policy Proposals

Sally C. Pipes joins the Lars Larson Show to question the Trump administration's latest action on drug pricing. President Trump plans to sign an executive order on Friday, July 24 that puts limits on drug pricing in the United States. Pipes explains that 90 percent of drugs are generic and already save most Americans a great deal of money. But the pending executive order ties the average reference drug price to those in other countries - Canada, UK, Germany, France,...

July 24, 2020 Issues, Policy Proposals

President Trump issued four executive orders Friday that he said will lower drug prices — but in reality, three of the orders will cause far more harm than good and represent electioneering at its worst. The three harmful executive orders allow the importation of drugs from Canada, reduce the price of insulin, and introduce an International Pricing Index for prescription drugs. The International Pricing Index will effectively impose price controls on prescription drugs under Medicare Part B — and in so doing, dramatically...

July 23, 2020 Issues, Policy Proposals

It’s not often that Joe Biden agrees with President Trump. But the former vice president found common ground with his presumptive opponent this month when he announced he would outline a plan to bring medical manufacturing back to the United States, something the president has long endorsed. This isn’t the first time political opponents have come together to support “Buy America” plans. Late last month, Sens. Marco Rubio, Florida Republican, and Elizabeth Warren, Massachusetts Democrat, introduced several bills designed to increase...

July 14, 2020 Coronavirus, Coronavirus Multimedia

Sally C. Pipes joined JT Nysewamder on Alabama Morning News in Birmingham to talk about the latest developments with the drug remdisivir. The drug, produced by Gilead, is being studied for potential use against COVID-19. Pipes and JT also discuss the cost of the drug, and how expensive it is to bring drugs to market in the United States. Listen to the interview here. ...

July 14, 2020 Coronavirus

More than eight in 10 Americans fear a second wave of the coronavirus outbreak, according to recent polling from Ipsos. Some cities and states have halted efforts to reopen their economies, in response to rising case counts. But there’s no reason to be fearful. We now have enough information about the coronavirus and its impact to continue reopening safely. If we put this knowledge to good use, we can craft policies that protect the most vulnerable while allowing those for whom the virus poses...

May 18, 2020 Blog, Coronavirus

It is expected that any day now, the White House will release an executive order requiring certain drugs to be manufactured in the United States. It's part of a wider push by both the administration and Congress to force the federal government to buy more American-made goods and reduce reliance on countries like China. This push is misguided. The administration's "Buy America" agenda would derail our response to COVID-19 and could have long-lasting negative consequences for our economy. The best way to maintain efficient, high-quality production of drugs and other medical equipment is...

May 11, 2020 Blog, Coronavirus

While many heroic doctors, nurses and other health care professionals are working long hours and risking their lives to treat COVID-19 patients, others have seen their workloads and hospital occupancy rates drop dramatically as a result of the coronavirus pandemic. This has created a financial crisis and endangered public health. At the onset of the COVID-19 outbreak, public health officials urged hospitals to suspend non-essential medical procedures. U.S. hospitals canceled tens of thousands of elective surgeries and other procedures, and urged...

April 28, 2020 Blog, Coronavirus, Policy Proposals

On ‘Supply-Chain Repatriation,’ It’s Buyer (and Nation) Beware By Scott Lincicome One of the most fashionable COVID-19 proposals being circulated by Washington politicians and pundits these days is the “repatriating” of global supply chains for pharmaceuticals, medical devices, and “personal protective equipment” that have been “outsourced” over the past three decades, leaving America utterly dependent on foreign countries, especially China, for these essential products. Bringing that manufacturing back home, so the story goes, is the only way to ensure future “resiliency” in...

April 27, 2020 Blog, Coronavirus, Policy Proposals

The presidential campaign of Sen. Bernie Sanders, I-Vt., may have ended, but his "Medicare-for-all" crusade marches on. Writing in The New York Times last week, Sanders argued that the coronavirus outbreak proved the government should take over our nation's health care system. Sanders isn't the only one championing "Medicare-for-all" in the wake of the pandemic. More than half of voters now say they support a single-payer system. But "Medicare-for-all" would not have improved our nation's response to the outbreak. Other countries with socialized medicine have struggled mightily to combat COVID-19. In fact, the United States would have been even...

April 21, 2020 Briefs, Price and Costs

Expanding “Buy America” rules for prescription drugs and medical supplies would reduce patient access to drugs and further damage the economy, finds a new issue brief released today by the Center for Medical Economics and Innovation at the Pacific Research Institute. Click here to download the brief “As the U.S. fights the coronavirus, policymakers must ensure that life-saving drugs are readily available to America’s patients,” said Sally Pipes, PRI President, CEO, and Thomas W. Smith Fellow in Health Care Studies and the...

April 14, 2020 Blog, Coronavirus, Policy Proposals

The coronavirus pandemic is threatening to stretch many hospitals to their breaking point. Beds are filling up with stricken patients, and public health officials are concerned about whether we'll have enough doctors and other healthcare professionals to care for them. So they're scrambling to roll back years' worth of regulations on the healthcare labor market—many of which never should've been in place to begin with. There's no shortage of red tape for policymakers to cut to boost the supply of care...

April 13, 2020 Blog, Coronavirus

Bill Gates announced on April 2 that his foundation would fund the construction of facilities to produce seven possible coronavirus vaccines. The Microsoft founder acknowledges that only two of those vaccines will likely succeed – and the foundation will thus waste billions of dollars on the failed candidates. That's a small price to pay to ensure the prompt delivery of vaccines, save countless lives and restart the economy, he says. And yet, "Billionaires should not exist," according to Sen. Bernie Sanders. "Every...

April 9, 2020 Blog, Coronavirus, Radio

Sally C. Pipes joined the the Pat Miller Show in Cincinnati, Ohio to discuss the enormous benefits of the American private sector in the fight against the coronavirus epidemic. Pipes breaks down how the private sector industries in the United States are pushing innovations in the fight against the coronavirus epidemic including necessary equipment and medical innovation. Click here to listen to the entire interview. ...

April 7, 2020 Blog, Coronavirus

In response to the coronavirus outbreak, the Centers for Medicare and Medicaid Services has rolled back regulations on hospitals and health care providers. Hospitals are no longer barred from treating COVID-19 patients in outpatient facilities. The feds are also freeing nurse practitioners, physician assistants and medical residents to provide more care on their own. CMS is even issuing waivers that allow hospitals to provide meals, laundry service and child care while health care personnel are working. Apparently, it takes a pandemic for policymakers to acknowledge that so...

April 6, 2020 Blog, Coronavirus

The new coronavirus outbreak has put enormous pressure on the American health care system. In response, federal officials and private insurers have rushed to improve patient access to video consultations and other forms of virtual care. It may have taken a public health emergency to bring “telehealth” to the mainstream, but these services are nothing new. We would do well to expand our reliance on telehealth long after COVID-19 is behind us. Telehealth involves the use of technology to deliver medical care...

March 30, 2020 Blog, Coronavirus

As scientists race to develop vaccines and treatments for COVID-19, Democrats in Congress have renewed their push for price controls on drugs designed to protect us from the respiratory disease caused by the coronavirus, along with other illnesses. The Democrats claim many Americans will only be able to afford the therapies that emerge if the government caps their prices. But price controls are a counterproductive way to bring down the cost of vaccines and drugs to treat diseases. They'd not only result in shortages...

March 25, 2020 Blog, Coronavirus, Innovation

Optimism is in short supply as the coronavirus pandemic grows deadlier by the day. COVID-19 has taken thousands of lives around the world and upended nearly every aspect of daily life. But there is at least one bright spot in this global public health emergency. That's the astounding speed with which private firms have begun tackling the problem. While federal regulators have exacerbated the crisis at seemingly every turn, private firms have rolled out promising new therapies and technologies that could...

February 7, 2020 Blog, Issues, Price and Costs

Swiss drugmaker Novartis recently launched a lottery-style program to allocate free doses of Zolgensma, its groundbreaking treatment for children with spinal muscular atrophy (SMA), to patients in countries that haven't approved the drug. But with a $2.1 million price tag, Zolgensma is inaccessible to some patients even where it has been approved. The prohibitive cost has been a source of criticism since the drug was approved. In a letter to the U.S. Food and Drug Administration's (FDA) Acting Commissioner last August, five U.S. senators, including presidential...

January 31, 2020 Blog, Policy Proposals

The White House Council of Economic Advisors just issued a damning indictment of a House bill (H.R. 3) designed to lower drug prices. According to White House economists, the measure endorsed by Nancy Pelosi and her fellow House Democrats could prevent the development of 100 new drugs over the next ten years. CEA concluded "the threat [the bill] poses to continued medical innovation will harm American patients in ways that far outweigh any benefits." This analysis is spot-on. That's why it's so surprising that...